Sugi Predict

Sugi Predict / Compounds / SCHEMBL2920504

SCHEMBL2920504

SCHEMBL2920504

NS(=O)(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 2/20 0.55
▸ CA1 P00915 8/20 0.53
▸ CA2 P00918 8/20 0.53
▸ CA9 Q16790 7/20 0.53
▸ CA12 O43570 4/20 0.53
▸ CES2 O00748 1/20 0.48
▸ MAPT P10636 3/20 0.45
▸ PTGS2 P35354 4/20 0.44
▸ PTGS1 P23219 3/20 0.44
▸ CA3 P07451 1/20 0.43
▸ APEX1 P27695 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26432672 0.90 KIF11 (0.47) KIF11CA1CA2CA9CA12
SCHEMBL819883 0.86 KIF11 (0.47) KIF11CA1CA2CA9CA12
Hydrochloric Acid SCHEMBL29968148 0.86 KIF11 (0.47) KIF11CA1CA2CA9CA12
SCHEMBL4807857 0.86 KIF11 (0.47) KIF11CA1CA2CA9CA12
SCHEMBL5363484 0.82 CA12 (0.48) KIF11CA1CA2CA9CA12
SCHEMBL25405645 0.81 KIF11 (0.43) KIF11CA1CA2CA9CA12
SCHEMBL7139803 0.81 CA2 (0.47) KIF11CA1CA2CA9CA12
SCHEMBL1510661 0.81 KIF11 (0.43) KIF11CA1CA2CA9CA12
SCHEMBL3507443 0.80 CES2 (0.52) KIF11CA1CA2CA9CA12
SCHEMBL21410215 0.80 CA2 (0.51) KIF11CA1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119219810-A Ionic polymer and preparation method and application thereof 佛山绿动氢能科技有限公司 2024-12-31 — — CN claimed
EP-1320531-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2010-09-08 — — EP claimed
WO-2003007955-A2 BIPHENYL APURINIC/APYRIMIDINIC SITE ENDONUCLEASE INHIBITORS TO TREAT CANCER CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-01-30 — — WO claimed
US-12534484-B2 Process for preparing dimeric phosphazene derived BrØnsted acids STUDIENGESELLSCHAFT KOHLE GGMBH (DE) 2026-01-27 — — US disclosed
EP-4200308-B1 PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS STUDIENGESELLSCHAFT KOHLE GGMBH (DE) 2025-09-10 — — EP disclosed
EP-3635022-B1 METHODS FOR MAKING FUNCTIONALIZED FLUORINATED MONOMERS, FLUORINATED MONOMERS, AND COMPOSITIONS FOR MAKING THE SAME ETNA TEC LTD (US) 2025-05-21 — — EP disclosed
CN-120005064-A Aryl ion polymer and preparation method and application thereof 佛山绿动氢能科技有限公司 2025-05-16 — — CN disclosed
CN-119219810-A Ionic polymer and preparation method and application thereof 佛山绿动氢能科技有限公司 2024-12-31 — — CN disclosed
CN-119219809-A Fluorine-containing polymer, preparation method thereof and ion exchange membrane 佛山绿动氢能科技有限公司 2024-12-31 — — CN disclosed
CN-118125984-A Benzenesulfonamide compound and preparation method and application thereof 中国药科大学 2024-06-04 — — CN disclosed
US-20230406870-A1 PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS STUDIENGESELLSCHAFT KOHLE GGMBH (DE) 2023-12-21 — — US disclosed
US-6774212-B2 FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-08-10 — — US disclosed
EP-1436253-A1 ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE Novartis AG (CH) 2004-07-14 — — EP disclosed
WO-2003031397-A1 ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE NOVARTIS AG (CH) 2003-04-17 — — WO disclosed
US-20020123468-A1 Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-09-05 — — US disclosed
US-5942546-A Sulfonyl-N-hydroxyguanidine derivatives DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 1999-08-24 — — US disclosed
US-4005199-A Substituted benzenesulfonamides as anthelmintics MERCK & CO., INC. (US) 1977-01-25 — — US disclosed
US-3987199-A PARASITICIDES MERCK & CO., INC. (US) 1976-10-19 — — US disclosed
US-3953493-A Substituted sulfonamide derivatives as anthelmintic agents MERCK & CO., INC. (US) 1976-04-27 — — US disclosed
US-3953492-A Anthelmintic substituted sulfonamide derivatives MERCK & CO., INC. (US) 1976-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230406870-A1 PROCESS FOR PREPARING DIMERIC PHOSPHAZENE DERIVED BRØNSTED ACIDS PHOSPHO1, BRPF1, BRD9 KIF11 3543/4885CA1 457/4885CA2 279/4885
US-12534484-B2 Process for preparing dimeric phosphazene derived BrØnsted acids HAT1, LBR, CD79B KIF11 4283/4885CA1 84/4885CA2 104/4885
US-20020123468-A1 Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease CES1, CYP51A1, SPINT2 KIF11 841/4885CA1 695/4885CA2 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.